AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.
Follow-Up Questions
What is AEON Biopharma Inc (AEON)'s P/E Ratio?
The P/E ratio of AEON Biopharma Inc is 0.3132
What is the price performance of AEON stock?
The current price of AEON is $1.09, it has decreased 0.9% in the last trading day.
What are the primary business themes or industries for AEON Biopharma Inc?
AEON Biopharma Inc belongs to N/A industry and the sector is N/A
What is AEON Biopharma Inc market cap?
AEON Biopharma Inc's current market cap is $40.4M
Is AEON Biopharma Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for AEON Biopharma Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
